Earlier this week, UK Prime Minister David Cameron revealed the formation of an independent review panel to address the growing threat of antibiotic resistance.
Responding to the announcement, Christopher Pace, GlobalData’s analyst covering infectious diseases, said: "Mr Cameron’s claim that inaction will result in “an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine” is a valid conclusion that has been echoed by experts interviewed by GlobalData.
Over the last two decades, many large pharmaceutical companies have abandoned antibiotic research due to the risky and prolonged R&D process, combined with the difficulty in commanding premium-pricing and the short durations of therapy, he pointed out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze